Market Analysis and Insights: Global COVID-19 Inactivated Vaccine Market
The global COVID-19 Inactivated Vaccine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global COVID-19 Inactivated Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global COVID-19 Inactivated Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global COVID-19 Inactivated Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global COVID-19 Inactivated Vaccine market.
COVID-19 Inactivated Vaccine Breakdown Data by Type
In Clinical Trials
Out-of-Clinical Trials
COVID-19 Inactivated Vaccine Breakdown Data by Application
Hospital
Clinic
Other
Based on regional and country-level analysis, the COVID-19 Inactivated Vaccine market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global COVID-19 Inactivated Vaccine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
Codagenix, Inc.
GeoVax, Inc.
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
The global COVID-19 Inactivated Vaccine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global COVID-19 Inactivated Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global COVID-19 Inactivated Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global COVID-19 Inactivated Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global COVID-19 Inactivated Vaccine market.
COVID-19 Inactivated Vaccine Breakdown Data by Type
In Clinical Trials
Out-of-Clinical Trials
COVID-19 Inactivated Vaccine Breakdown Data by Application
Hospital
Clinic
Other
Based on regional and country-level analysis, the COVID-19 Inactivated Vaccine market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global COVID-19 Inactivated Vaccine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
Codagenix, Inc.
GeoVax, Inc.
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 Inactivated Vaccine Market Size Growth Rate by Type (2021-2027)
1.2.2 In Clinical Trials
1.2.3 Out-of-Clinical Trials
1.3 Market by Application
1.3.1 Global COVID-19 Inactivated Vaccine Market Share by Application (2021-2027)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global COVID-19 Inactivated Vaccine Market Size
2.2 COVID-19 Inactivated Vaccine Market Size by Regions
2.2.1 COVID-19 Inactivated Vaccine Growth Rate by Regions (2021-2027)
2.2.2 COVID-19 Inactivated Vaccine Market Share by Regions (2021-2027)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases
3 Key Players
3.1 COVID-19 Inactivated Vaccine Revenue by Players (2020-2021)
3.2 COVID-19 Inactivated Vaccine Key Players Headquaters and Area Served
3.3 Key Players COVID-19 Inactivated Vaccine Product/Solution/Service
3.4 Date of Enter into COVID-19 Inactivated Vaccine Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and by Application
4.1 Global COVID-19 Inactivated Vaccine Market Size by Type (2021-2027)
4.2 Global COVID-19 Inactivated Vaccine Market Size by Application (2021-2027)
5 North America
5.1 North America COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
5.2 COVID-19 Inactivated Vaccine Key Players in North America
5.3 North America COVID-19 Inactivated Vaccine Market Size by Type
5.4 North America COVID-19 Inactivated Vaccine Market Size by Application
6 Europe
6.1 Europe COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
6.2 COVID-19 Inactivated Vaccine Key Players in Europe
6.3 Europe COVID-19 Inactivated Vaccine Market Size by Type
6.4 Europe COVID-19 Inactivated Vaccine Market Size by Application
7 Japan
7.1 Japan COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
7.2 COVID-19 Inactivated Vaccine Key Players in Europe
7.3 Japan COVID-19 Inactivated Vaccine Market Size by Type
7.4 Japan COVID-19 Inactivated Vaccine Market Size by Application
8 Rest of World
8.1 China
8.1.1 China COVID-19 Inactivated Vaccine Market Analysis
8.1.2 Key Players in China
8.2 Southeast Asia
8.2.1 Southeast Asia COVID-19 Inactivated Vaccine Market Analysis
8.2.2 Key Players in Southeast Asia
8.3 India
8.3.1 India COVID-19 Inactivated Vaccine Market Analysis
8.3.2 Key Players in India
9 International Player Profiles
9.1 Inovio Pharmaceuticals
9.1.1 Inovio Pharmaceuticals Company Details
9.1.2 Inovio Pharmaceuticals Description and Business Overview
9.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Introduction
9.1.4 Inovio Pharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.1.5 Inovio Pharmaceuticals Recent Development
9.2 Takis Biotech (Evvivax)
9.2.1 Takis Biotech (Evvivax) Company Details
9.2.2 Takis Biotech (Evvivax) Description and Business Overview
9.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Introduction
9.2.4 Takis Biotech (Evvivax) Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.2.5 Takis Biotech (Evvivax) Recent Development
9.3 Zydus Cadila
9.3.1 Zydus Cadila Company Details
9.3.2 Zydus Cadila Description and Business Overview
9.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Introduction
9.3.4 Zydus Cadila Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.3.5 Zydus Cadila Recent Development
9.4 Codagenix, Inc.
9.4.1 Codagenix, Inc. Company Details
9.4.2 Codagenix, Inc. Description and Business Overview
9.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Introduction
9.4.4 Codagenix, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.4.5 Codagenix, Inc. Recent Development
9.5 GeoVax, Inc.
9.5.1 GeoVax, Inc. Company Details
9.5.2 GeoVax, Inc. Description and Business Overview
9.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Introduction
9.5.4 GeoVax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.5.5 GeoVax, Inc. Recent Development
9.6 Bravovax
9.6.1 Bravovax Company Details
9.6.2 Bravovax Description and Business Overview
9.6.3 Bravovax COVID-19 Inactivated Vaccine Introduction
9.6.4 Bravovax Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.6.5 Bravovax Recent Development
9.7 Janssen Pharmaceutical Companies
9.7.1 Janssen Pharmaceutical Companies Company Details
9.7.2 Janssen Pharmaceutical Companies Description and Business Overview
9.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Introduction
9.7.4 Janssen Pharmaceutical Companies Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.7.5 Janssen Pharmaceutical Companies Recent Development
9.8 Altimmune
9.8.1 Altimmune Company Details
9.8.2 Altimmune Description and Business Overview
9.8.3 Altimmune COVID-19 Inactivated Vaccine Introduction
9.8.4 Altimmune Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.8.5 Altimmune Recent Development
9.9 Vaxart
9.9.1 Vaxart Company Details
9.9.2 Vaxart Description and Business Overview
9.9.3 Vaxart COVID-19 Inactivated Vaccine Introduction
9.9.4 Vaxart Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.9.5 Vaxart Recent Development
9.10 CanSino Biologics
9.10.1 CanSino Biologics Company Details
9.10.2 CanSino Biologics Description and Business Overview
9.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Introduction
9.10.4 CanSino Biologics Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.10.5 CanSino Biologics Recent Development
9.11 ExpreS2ion Biotechnologies ApS
9.11.1 ExpreS2ion Biotechnologies ApS Company Details
9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview
9.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Introduction
9.11.4 ExpreS2ion Biotechnologies ApS Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.11.5 ExpreS2ion Biotechnologies ApS Recent Development
9.12 Clover Biopharmaceuticals
9.12.1 Clover Biopharmaceuticals Company Details
9.12.2 Clover Biopharmaceuticals Description and Business Overview
9.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Introduction
9.12.4 Clover Biopharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.12.5 Clover Biopharmaceuticals Recent Development
9.13 GSK
9.13.1 GSK Company Details
9.13.2 GSK Description and Business Overview
9.13.3 GSK COVID-19 Inactivated Vaccine Introduction
9.13.4 GSK Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.13.5 GSK Recent Development
9.14 Vaxil Bio Ltd.
9.14.1 Vaxil Bio Ltd. Company Details
9.14.2 Vaxil Bio Ltd. Description and Business Overview
9.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Introduction
9.14.4 Vaxil Bio Ltd. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.14.5 Vaxil Bio Ltd. Recent Development
9.15 Generex
9.15.1 Generex Company Details
9.15.2 Generex Description and Business Overview
9.15.3 Generex COVID-19 Inactivated Vaccine Introduction
9.15.4 Generex Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.15.5 Generex Recent Development
9.16 Novavax, Inc.
9.16.1 Company Details
9.16.2 Novavax, Inc. Description and Business Overview
9.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Introduction
9.16.4 Novavax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.16.5 Novavax, Inc. Recent Development
9.17 Sanofi Pasteur
9.17.1 Sanofi Pasteur Company Details
9.17.2 Sanofi Pasteur Description and Business Overview
9.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Introduction
9.17.4 Sanofi Pasteur Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.17.5 Sanofi Pasteur Recent Development
9.18 Baylor
9.18.1 Baylor Company Details
9.18.2 Baylor Description and Business Overview
9.18.3 Baylor COVID-19 Inactivated Vaccine Introduction
9.18.4 Baylor Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.18.5 Baylor Recent Development
9.18 iBio, Inc.
.1 iBio, Inc. Company Details
.2 iBio, Inc. Description and Business Overview
.3 iBio, Inc. COVID-19 Inactivated Vaccine Introduction
.4 iBio, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
.5 iBio, Inc. Recent Development
9.20 Moderna, Inc.
9.20.1 Moderna, Inc. Company Details
9.20.2 Moderna, Inc. Description and Business Overview
9.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Introduction
9.20.4 Moderna, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.20.5 Moderna, Inc. Recent Development
9.21 Curevac
9.21.1 Curevac Company Details
9.21.2 Curevac Description and Business Overview
9.21.3 Curevac COVID-19 Inactivated Vaccine Introduction
9.21.4 Curevac Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.21.5 Curevac Recent Development
9.22 ImmunoPrecise
9.22.1 ImmunoPrecise Company Details
9.22.2 ImmunoPrecise Description and Business Overview
9.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Introduction
9.22.4 ImmunoPrecise Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.22.5 ImmunoPrecise Recent Development
10 Market Dynamics
10.1 Industry Trends
10.2 Market Drives
10.3 Market Challenges
10.4 Market Restraints
11 Key Findings in This Report
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 Inactivated Vaccine Market Size Growth Rate by Type (2021-2027)
1.2.2 In Clinical Trials
1.2.3 Out-of-Clinical Trials
1.3 Market by Application
1.3.1 Global COVID-19 Inactivated Vaccine Market Share by Application (2021-2027)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global COVID-19 Inactivated Vaccine Market Size
2.2 COVID-19 Inactivated Vaccine Market Size by Regions
2.2.1 COVID-19 Inactivated Vaccine Growth Rate by Regions (2021-2027)
2.2.2 COVID-19 Inactivated Vaccine Market Share by Regions (2021-2027)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases
3 Key Players
3.1 COVID-19 Inactivated Vaccine Revenue by Players (2020-2021)
3.2 COVID-19 Inactivated Vaccine Key Players Headquaters and Area Served
3.3 Key Players COVID-19 Inactivated Vaccine Product/Solution/Service
3.4 Date of Enter into COVID-19 Inactivated Vaccine Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and by Application
4.1 Global COVID-19 Inactivated Vaccine Market Size by Type (2021-2027)
4.2 Global COVID-19 Inactivated Vaccine Market Size by Application (2021-2027)
5 North America
5.1 North America COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
5.2 COVID-19 Inactivated Vaccine Key Players in North America
5.3 North America COVID-19 Inactivated Vaccine Market Size by Type
5.4 North America COVID-19 Inactivated Vaccine Market Size by Application
6 Europe
6.1 Europe COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
6.2 COVID-19 Inactivated Vaccine Key Players in Europe
6.3 Europe COVID-19 Inactivated Vaccine Market Size by Type
6.4 Europe COVID-19 Inactivated Vaccine Market Size by Application
7 Japan
7.1 Japan COVID-19 Inactivated Vaccine Market Forecast (2021-2027)
7.2 COVID-19 Inactivated Vaccine Key Players in Europe
7.3 Japan COVID-19 Inactivated Vaccine Market Size by Type
7.4 Japan COVID-19 Inactivated Vaccine Market Size by Application
8 Rest of World
8.1 China
8.1.1 China COVID-19 Inactivated Vaccine Market Analysis
8.1.2 Key Players in China
8.2 Southeast Asia
8.2.1 Southeast Asia COVID-19 Inactivated Vaccine Market Analysis
8.2.2 Key Players in Southeast Asia
8.3 India
8.3.1 India COVID-19 Inactivated Vaccine Market Analysis
8.3.2 Key Players in India
9 International Player Profiles
9.1 Inovio Pharmaceuticals
9.1.1 Inovio Pharmaceuticals Company Details
9.1.2 Inovio Pharmaceuticals Description and Business Overview
9.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Introduction
9.1.4 Inovio Pharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.1.5 Inovio Pharmaceuticals Recent Development
9.2 Takis Biotech (Evvivax)
9.2.1 Takis Biotech (Evvivax) Company Details
9.2.2 Takis Biotech (Evvivax) Description and Business Overview
9.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Introduction
9.2.4 Takis Biotech (Evvivax) Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.2.5 Takis Biotech (Evvivax) Recent Development
9.3 Zydus Cadila
9.3.1 Zydus Cadila Company Details
9.3.2 Zydus Cadila Description and Business Overview
9.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Introduction
9.3.4 Zydus Cadila Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.3.5 Zydus Cadila Recent Development
9.4 Codagenix, Inc.
9.4.1 Codagenix, Inc. Company Details
9.4.2 Codagenix, Inc. Description and Business Overview
9.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Introduction
9.4.4 Codagenix, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.4.5 Codagenix, Inc. Recent Development
9.5 GeoVax, Inc.
9.5.1 GeoVax, Inc. Company Details
9.5.2 GeoVax, Inc. Description and Business Overview
9.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Introduction
9.5.4 GeoVax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.5.5 GeoVax, Inc. Recent Development
9.6 Bravovax
9.6.1 Bravovax Company Details
9.6.2 Bravovax Description and Business Overview
9.6.3 Bravovax COVID-19 Inactivated Vaccine Introduction
9.6.4 Bravovax Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.6.5 Bravovax Recent Development
9.7 Janssen Pharmaceutical Companies
9.7.1 Janssen Pharmaceutical Companies Company Details
9.7.2 Janssen Pharmaceutical Companies Description and Business Overview
9.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Introduction
9.7.4 Janssen Pharmaceutical Companies Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.7.5 Janssen Pharmaceutical Companies Recent Development
9.8 Altimmune
9.8.1 Altimmune Company Details
9.8.2 Altimmune Description and Business Overview
9.8.3 Altimmune COVID-19 Inactivated Vaccine Introduction
9.8.4 Altimmune Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.8.5 Altimmune Recent Development
9.9 Vaxart
9.9.1 Vaxart Company Details
9.9.2 Vaxart Description and Business Overview
9.9.3 Vaxart COVID-19 Inactivated Vaccine Introduction
9.9.4 Vaxart Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.9.5 Vaxart Recent Development
9.10 CanSino Biologics
9.10.1 CanSino Biologics Company Details
9.10.2 CanSino Biologics Description and Business Overview
9.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Introduction
9.10.4 CanSino Biologics Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.10.5 CanSino Biologics Recent Development
9.11 ExpreS2ion Biotechnologies ApS
9.11.1 ExpreS2ion Biotechnologies ApS Company Details
9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview
9.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Introduction
9.11.4 ExpreS2ion Biotechnologies ApS Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.11.5 ExpreS2ion Biotechnologies ApS Recent Development
9.12 Clover Biopharmaceuticals
9.12.1 Clover Biopharmaceuticals Company Details
9.12.2 Clover Biopharmaceuticals Description and Business Overview
9.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Introduction
9.12.4 Clover Biopharmaceuticals Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.12.5 Clover Biopharmaceuticals Recent Development
9.13 GSK
9.13.1 GSK Company Details
9.13.2 GSK Description and Business Overview
9.13.3 GSK COVID-19 Inactivated Vaccine Introduction
9.13.4 GSK Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.13.5 GSK Recent Development
9.14 Vaxil Bio Ltd.
9.14.1 Vaxil Bio Ltd. Company Details
9.14.2 Vaxil Bio Ltd. Description and Business Overview
9.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Introduction
9.14.4 Vaxil Bio Ltd. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.14.5 Vaxil Bio Ltd. Recent Development
9.15 Generex
9.15.1 Generex Company Details
9.15.2 Generex Description and Business Overview
9.15.3 Generex COVID-19 Inactivated Vaccine Introduction
9.15.4 Generex Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.15.5 Generex Recent Development
9.16 Novavax, Inc.
9.16.1 Company Details
9.16.2 Novavax, Inc. Description and Business Overview
9.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Introduction
9.16.4 Novavax, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.16.5 Novavax, Inc. Recent Development
9.17 Sanofi Pasteur
9.17.1 Sanofi Pasteur Company Details
9.17.2 Sanofi Pasteur Description and Business Overview
9.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Introduction
9.17.4 Sanofi Pasteur Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.17.5 Sanofi Pasteur Recent Development
9.18 Baylor
9.18.1 Baylor Company Details
9.18.2 Baylor Description and Business Overview
9.18.3 Baylor COVID-19 Inactivated Vaccine Introduction
9.18.4 Baylor Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.18.5 Baylor Recent Development
9.18 iBio, Inc.
.1 iBio, Inc. Company Details
.2 iBio, Inc. Description and Business Overview
.3 iBio, Inc. COVID-19 Inactivated Vaccine Introduction
.4 iBio, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
.5 iBio, Inc. Recent Development
9.20 Moderna, Inc.
9.20.1 Moderna, Inc. Company Details
9.20.2 Moderna, Inc. Description and Business Overview
9.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Introduction
9.20.4 Moderna, Inc. Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.20.5 Moderna, Inc. Recent Development
9.21 Curevac
9.21.1 Curevac Company Details
9.21.2 Curevac Description and Business Overview
9.21.3 Curevac COVID-19 Inactivated Vaccine Introduction
9.21.4 Curevac Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.21.5 Curevac Recent Development
9.22 ImmunoPrecise
9.22.1 ImmunoPrecise Company Details
9.22.2 ImmunoPrecise Description and Business Overview
9.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Introduction
9.22.4 ImmunoPrecise Revenue in COVID-19 Inactivated Vaccine Business (2020-2021)
9.22.5 ImmunoPrecise Recent Development
10 Market Dynamics
10.1 Industry Trends
10.2 Market Drives
10.3 Market Challenges
10.4 Market Restraints
11 Key Findings in This Report
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details
